Monday, May 14, 2018
This article from CureToday explains why seeking palliative care for symptom management of the physical and emotional consequences of treatment to enhance one's quality of life is just as important as seeking chemotherapy.
To read more about the impact on palliative care while undergoing treatment for ovarian cancer, follow this link.
Thursday, May 10, 2018
For those of us who are NEDs ("no evidence of disease") and for those of us who are in recurrence, one thing we all have in common is that our life before cancer is radically different to life after cancer.
What is your new normal looking like?
In this article from CureToday, Bonnie Annis, a breast cancer survivor, explains why her new normal isn't quite so new anymore. You can read about her experiences but we'd love to hear about yours. You can tell us about this on the comment section below.
Friday, May 4, 2018
Before I go into the results, please note that this study was conducted on cell cultures. This means that research has not progressed to human clinical studies.
Researchers in this study show how curcumin aids in inhibiting certain pathways to cancer cell growth. Using 20 µm of curcumin inhibited a protein that triggers a key signaling factor. This signaling factor enables the cancer cell to grow and to undergo certain transitions that enable it to metastasize.
The study authors used curcumin as a single agent and in conjunction with doxorubicin (DOX). DOX is used to treat recurrent ovarian cancer. Interestingly, when used in combination, DOX actually enhanced the effectiveness of curcumin in inhibiting specific proteins and pathways implicated in ovarian cancer cell growth and metastasis.
To read this article, follow this link.
As always, your thoughts and comments are welcomed!
The article describes a new screening tool being studied to detect endometrial and ovarian cancer in its early stages.
Called PapSEEK, this liquid biopsy is actually a PAP test that checks for cancer related DNA changes. Preliminary investigations showed that it detected 33% of ovarian cancers (of which 34% were detected in early stages) and ~81% of endometrial cancers (of which 78% were detected in early stages).
These results were first published in the journal Science: Translational Medicine and was reported on the National Cancer Institute web site. Follow this link to read NCI's article.
For more information about this event, follow this link.
Wednesday, May 2, 2018
This publication is available as a free download and you can access it by following this link.
Here's the official description of the book: